Overview

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Status:
Completed

Trial end date:
2020-06-04

Target enrollment:

Participant gender:

Summary

A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in utero in any tanezumb study.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Collaborator:

Eli Lilly and Company